Acquired C3 Deficiency in Patients with Alcoholic Cirrhosis Predisposes to Infection and Increased Mortality

Overview

Journal Gut

Specialty Gastroenterology

Date 1997 Apr 1

PMID 9176087

Citations 47

Authors

C Homann

K Varming

K Hogasen

T E Mollnes

N Graudal

A C Thomsen

P Garred

Affiliations

Soon will be listed here.

Abstract

Background: Acquired deficiencies of certain complement proteins and impaired opsonisation activity have been implicated in the pathogenesis of the increased susceptibility to infections of patients with alcoholic cirrhosis.

Methods: Serum concentrations of C3 and C4, plasma concentrations of C3bc, C9, and the terminal C5b-9 complement complex (TCC), and haemolytic complement activity (classic and alternative pathway) of serum, and serum opsonic activity were determined in 46 patients with compensated alcoholic cirrhosis, 31 who were decompensated, and in 15 healthy subjects. After 19 months (median) the investigated variables were analysed for their use in prognosis of recurrent infections and survival.

Results: C3 and C4 concentrations and the haemolytic complement activity of the alternative pathway were decreased in decompensated cirrhotic patients compared with controls (p < 0.01). Univariate analysis (log rank test) showed that low concentrations (< or = lower quartile) of C3 (p < 0.001) and C3bc (p < 0.05), haemolytic complement activity of the alternative pathway (p < 0.01) and classic pathway (p < 0.05), and decompensated cirrhosis (p < 0.001) were associated with an increased risk of infection and increased mortality. Multivariate (Cox) analysis showed that low C3 concentrations and decompensation of cirrhosis were significant predictors of infections and mortality (p < 0.02).

Conclusions: Low serum C3 concentrations and decreased haemolytic complement function predisposes to infection and increased mortality in patients with alcoholic cirrhosis.

Citing Articles

Transcriptomic and metabolomic analyses reveal the spatial role of carnitine metabolism in the progression of hepatitis B virus cirrhosis to hepatocellular carcinoma.

Gao P, Liu Q, Luo Z, Pu W Front Microbiol. 2024; 15:1461456.

PMID: 39735192 PMC: 11671487. DOI: 10.3389/fmicb.2024.1461456.

Macrophage Evolution during Progression of Hepatitis Virus B-Related Acute-on-Chronic Liver Failure.

Rao J, Ye D, Ren A, He W, Zhang X, Chen P J Innate Immun. 2024; 17(1):29-43.

PMID: 39637841 PMC: 11753795. DOI: 10.1159/000542946.

Case Study and Genomic Analysis of a Hypervirulent ST25 Strain in a Liver Cirrhosis Patient.

Wang Y Infect Drug Resist. 2024; 17:4205-4212.

PMID: 39355781 PMC: 11444233. DOI: 10.2147/IDR.S487700.

Liver Cirrhosis: The Immunocompromised State.

Rodriguez-Negrete E, Galvez-Martinez M, Sanchez-Reyes K, Fajardo-Felix C, Perez-Resendiz K, Madrigal-Santillan E J Clin Med. 2024; 13(18).

PMID: 39337069 PMC: 11432654. DOI: 10.3390/jcm13185582.

Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis.

Simbrunner B, Hartl L, Jachs M, Bauer D, Scheiner B, Hofer B JHEP Rep. 2023; 5(5):100712.

PMID: 37035457 PMC: 10074195. DOI: 10.1016/j.jhepr.2023.100712.

References

Such J, Guarner C, Enriquez J, Rodriguez J, Seres I, Vilardell F . Low C3 in cirrhotic ascites predisposes to spontaneous bacterial peritonitis. J Hepatol. 1988; 6(1):80-4. DOI: 10.1016/s0168-8278(88)80465-3. View

Christensen E . Multivariate survival analysis using Cox's regression model. Hepatology. 1987; 7(6):1346-58. DOI: 10.1002/hep.1840070628. View

Lumsden A, Henderson J, Kutner M . Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology. 1988; 8(2):232-6. DOI: 10.1002/hep.1840080207. View

Runyon B . Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis. Hepatology. 1988; 8(3):632-5. DOI: 10.1002/hep.1840080332. View

Ellison 3rd R, Horsburgh Jr C, Curd J . Complement levels in patients with hepatic dysfunction. Dig Dis Sci. 1990; 35(2):231-5. DOI: 10.1007/BF01536768. View

Mal F, Huu T, Bendahou M, Trinchet J, Garnier M, Hakim J . Chemoattractant and opsonic activity in ascitic fluid. A study in 47 patients with cirrhosis or malignant peritonitis. J Hepatol. 1991; 12(1):45-9. DOI: 10.1016/0168-8278(91)90907-s. View

Mollnes T, Redl H, Hogasen K, Bengtsson A, Garred P, Speilberg L . Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol. 1993; 91(2):295-300. PMC: 1554676. DOI: 10.1111/j.1365-2249.1993.tb05898.x. View

Andreu M, Sola R, Sitges-Serra A, Alia C, Gallen M, Vila M . Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology. 1993; 104(4):1133-8. DOI: 10.1016/0016-5085(93)90284-j. View

Homann C, Garred P, Graudal N, Hasselqvist P, Christiansen M, Fagerhol M . Plasma calprotectin: a new prognostic marker of survival in alcohol-induced cirrhosis. Hepatology. 1995; 21(4):979-85. View

10.

Homann C, Garred P, Hasselqvist P, Graudal N, Thiel S, Thomsen A . Mannan-binding protein and complement dependent opsonization in alcoholic cirrhosis. Liver. 1995; 15(1):39-44. DOI: 10.1111/j.1600-0676.1995.tb00105.x. View

11.

Wessels M, Butko P, Ma M, WARREN H, Lage A, Carroll M . Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci U S A. 1995; 92(25):11490-4. PMC: 40427. DOI: 10.1073/pnas.92.25.11490. View

12.

Fox R, DUDLEY F, Sherlock S . The serum concentration of the third component of complement beta-1C-beta-1A in liver disease. Gut. 1971; 12(7):574-8. PMC: 1411859. DOI: 10.1136/gut.12.7.574. View

13.

Finlayson N, Krohn K, Fauconnet M, Anderson K . Significance of serum complement levels in chronic liver disease. Gastroenterology. 1972; 63(4):653-9. View

14.

Potter B, Trueman A, Jones E . Serum complement in chronic liver disease. Gut. 1973; 14(6):451-6. PMC: 1412744. DOI: 10.1136/gut.14.6.451. View

15.

Kourilsky O, Leroy C, Peltier A . Complement and liver cell function in 53 patients with liver disease. Am J Med. 1973; 55(6):783-90. DOI: 10.1016/0002-9343(73)90259-3. View

16.

Agnello V . Complement deficiency states. Medicine (Baltimore). 1978; 57(1):1-23. DOI: 10.1097/00005792-197801000-00001. View

17.

Polhill Jr R, Pruitt K, JOHNSTON Jr R . Kinetic assessment of alternative complement pathway activity in a hemolytic system. I. Experimental and mathematical analyses. J Immunol. 1978; 121(1):363-70. View

18.

Ferrante A, Thong Y . A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the Hypaque-Ficoll technique. J Immunol Methods. 1978; 24(3-4):389-93. DOI: 10.1016/0022-1759(78)90143-6. View

19.

Potter B, Elias E, Fayers P, Jones E . Profiles of serum complement in patients with hepatobiliary diseases. Digestion. 1978; 18(5-6):371-83. DOI: 10.1159/000198223. View

20.

Horwitz M . Phagocytosis of microorganisms. Rev Infect Dis. 1982; 4(1):104-23. DOI: 10.1093/clinids/4.1.104. View